New treatments for malaria using proteasome inhibitors
Selective Plasmodium proteasome inhibitors as novel multi-stage antimalarials
['FUNDING_R01'] · WEILL MEDICAL COLL OF CORNELL UNIV · NIH-10981978
This study is looking at new ways to fight malaria by creating drugs that target a specific part of the malaria parasite, with the hope of making existing treatments even better and helping to protect those most at risk.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WEILL MEDICAL COLL OF CORNELL UNIV (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-10981978 on ClinicalTrials.gov |
What this research studies
This research focuses on developing novel antimalarial drugs that target the proteasome of the malaria parasite, Plasmodium. By inhibiting the proteasome, the study aims to disrupt the parasite's life cycle at multiple stages, including its transmission and liver stages. The approach involves testing these inhibitors in combination with existing treatments like artemisinins to enhance their effectiveness. The ultimate goal is to create therapies that can prevent, treat, and block the transmission of malaria, particularly in vulnerable populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under the age of five living in malaria-endemic regions, particularly in Sub-Saharan Africa.
Not a fit: Patients who are not affected by malaria or those living outside of malaria-endemic areas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for malaria, significantly reducing the disease's impact on children and communities in affected regions.
How similar studies have performed: Previous research has shown promise in targeting the proteasome for treating various diseases, including cancer, indicating a potential for success in this novel application for malaria.
Where this research is happening
NEW YORK, UNITED STATES
- WEILL MEDICAL COLL OF CORNELL UNIV — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIN, GANG — WEILL MEDICAL COLL OF CORNELL UNIV
- Study coordinator: LIN, GANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.